| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.097 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.088 | 0.03 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.089 | 0.03 |